Gilead to test inhaled version of remdesivir on Covid-19 patients in August
The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals
An ampule of Ebola drug remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues/ Reuters
Gilead Sciences Inc said on Monday that it plans to begin clinical trials of an inhaled version of its antiviral treatment remdesivir for Covid-19 patients in August.
The drug is currently used intravenously and an inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside hospitals, the company said in a statement.
Keep updated, follow The Business Standard's Google news channel
